Adage Capital Partners Gp, L.L.C. Travere Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,184,898 shares of TVTX stock, worth $36.9 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,184,898
Previous 376,800
479.86%
Holding current value
$36.9 Million
Previous $6.56 Million
496.57%
% of portfolio
0.08%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$150 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$129 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$127 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$84.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$81.1 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.09B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...